AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01389284 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Naproxen Sodium IR Placebo
Description: Matching placebo of 220 mg Naproxen Sodium IR (Aleve) for 24 hours
Study NCT02216877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mablet 360 mg
Study NCT02216877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT02216877 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00784927 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Study NCT00784927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study NCT00784927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Study NCT00784927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Study NCT00371761 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa-2b (PegIntron)
Description: Powder for injection in vials ( 100, and 120 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 24 weeks
Study NCT03351296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: temozolomide 200 mg/m² once daily, days 10-14, every 28 days
Study NCT03351296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: bevacizumab 5 mg/kg every 14 days
Study NCT03369535 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: CARB rich diet
Description: Consumed CARB rich diet for 6 weeks with a washout period of at least 2 weeks before the next intervention
Study NCT03369535 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CARB rich diet
Description: Consumed CARB rich diet for 6 weeks with a washout period of at least 2 weeks before the next intervention
Study NCT03369535 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: MUFA rich diet
Description: Consumed MUFA rich diet for 6 weeks with a washout period of at least 2 weeks before the next intervention
Study NCT03369535 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MUFA rich diet
Description: Consumed MUFA rich diet for 6 weeks with a washout period of at least 2 weeks before the next intervention
Study NCT03369535 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: PROT rich diet
Description: Consumed PROT rich diet for 6 weeks with a washout period of at least 2 weeks before the next intervention
Study NCT03369535 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PROT rich diet
Description: Consumed PROT rich diet for 6 weeks with a washout period of at least 2 weeks before the next intervention
Study NCT00070291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Cyclosporine doses will be based on actual body weight unless actual body weight is > 15 kg higher than the ideal body weight. Cyclosporine dose will be adjusted to maintain a trough whole blood level of 250-450 ng/mL during the high dose period (weeks 1 -6, starting dose will begin at cyclosporine 3 mg/kg by mouth two times a day (PO BID)) and 150-250 ng/mL during the maintenance period (weeks 7-36, maintenance dose will begin at cyclosporine 2 mg/kg PO BID) in the absence of renal toxicity
Study NCT00371761 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adefovir dipivoxil (adefovir)
Description: 10 mg adefovir dipivoxil (equivalent to 5.4.5 mg adefovir) tablets, oral, dose of 1 tablet per day for up to 48 weeks
Study NCT03361176 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Injectable sodium deoxycholate
Description: Kybella(TM) alone: 2 mg/cm2 of Kybella(TM) with 0.2 mL of 1% lidocaine with no epinephrine plus 0.2cc saline to the non-TMC group to maintain equal concentrations in each injection so that the final Kybella concentration per vial will be 10mg/1.2mls or 1.6mg per 0.2 cc injection point will be delivered in up to 50 injections spaced 1.0 cm apart at 0.2 mL/injection for a total maximal dose of up to 100 mg of SDOC.
Study NCT03361176 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Injectable sodium deoxycholate with Triamcinolone acetate
Description: Kybella(TM)+TMC at 1.0 mg/mL: 2.0 mL of 2 mg/cm2 of Kybella(TM) will be mixed with 0.2 mL of 10 mg/mL of triamcinolone acetate, 0.2 mL of 1% lidocaine with no epinephrine and then delivered in up to 50 injections spaced 1.0 cm apart at 0.2 mL/injection for a total dose of up to 100 mg of SDOC using a 30 gauge (or smaller) 0.5-inch needle. The final Kybella concentration per vial will be 10mg/1.2mls or 1.6mg per 0.2 cc injection point
Study NCT02496507 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sit-stand workstation
Description: After baseline, each participant had a sit-stand workstation installed on their existing workplace desk. A single or dual monitor WorkFit-A with Worksurface+ workstation was installed, dependent on the number of monitors. The monitor(s) and keyboard were housed on the workstation and the workstation could be quickly raised up and down by hand to enable seated or standing work. Participants were not prescribed an amount of time to use the station. Ergotron Ltd provided and installed the workstations and gave participants basic face-to-face training and ergonomic information on correct use. Participants received a web link to manufacturer ergonomic guidelines via an email from the research team. After end-intervention data collection, manufacturer staff uninstalled the workstations.
Study NCT03718299 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Injections of tildrakizumab
Description: given at Week 0, Week 4, Week 16, Week 28, Week 40 and Week 52
Study NCT02111980 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RF Assure Scanning
Description: CIED and temporary pacemaker patients will be scanned with RF surgical sponge detection wand and mat as well as with and without the RF sponge. The scanning will only be conducted on the device scheduled for removal. Patients will have device interrogated before and after scanning (for CIEDs) to determine if there have been any clinically significant changes in programming or settings due to scanning with RF technology. Vitals will be monitored and recorded before, during, and after scanning.
Study NCT05142644 — intervention group
Intervention type: PROCEDURE
Intervention: ultrasound
Description: An extra ultrasound performed during pregnancy
Study NCT01862029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast
Description: Selective phosphodiesterase 4 (PDE4) inhibitor
Study NCT01348971 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sodium nitrate
Description: Preoperative oral administration of sodium nitrate. 700 mg the night before surgery and 700 mg three hours before surgery
Study NCT01348971 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride
Description: Preoperative oral administration of sodium chloride the night before surgery and three hours before surgery
Study NCT01389362 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chinese herbal medicine (Radix Rehmanniae and Radix Astragali)
Description: 2 sachets to be taken daily
Study NCT01389362 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: 2 sachets to be taken daily
Study NCT01728961 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether/Lumefantrine (AL)
Study NCT03254147 — intervention group
Intervention type: DRUG
Intervention: warfarin
Description: warfarin
Study NCT04306185 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: OVARIAN FRAGMENTATION
Description: BILATERAL OVARIAN CORTEX FRAGMENTATION USING LAPAROSCOPIC SCISSORS
Study NCT04577339 — intervention group
Intervention type: PROCEDURE
Intervention: Laparotomy or laparoscopy
Description: Laparotomy is the opening of the abdominal cavity usually through a midline incision.~Laparoscopy is using minimal access keyhole surgery to perform the surgery instead of laparotomy Interventional radiology is the use of imaging to perform a procedure on the abdomen without surgery, for example, using ultrasound to guide a needle to drain an abscess Best supportive care is usually end-of-life care concentration on relieving symptoms rather than treating the cause.
Study NCT00934323 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amaryl M SR 1/500 mg
Description: single oral administration in period 1 for TR sequential group, and in period 2 for RT sequential group
Study NCT00934323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amaryl M SR 1/500 mg
Description: single oral administration in period 1 for TR sequential group, and in period 2 for RT sequential group
Study NCT00934323 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amaryl M SR 2/500 mg
Description: single oral administration in period 2 for TR sequential group, and in period 2 for RT sequential group
Study NCT00934323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amaryl M SR 2/500 mg
Description: single oral administration in period 2 for TR sequential group, and in period 2 for RT sequential group
Study NCT01539096 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tDCS: noninvasive brain stimulation
Description: TDCS is a method of noninvasive stimulation of the brain. Using electrodes placed in saline-soaked sponges, low level of direct current (1mA) is delivered over the scalp. This intervention is considered safe and noninvasive because it does not involve implantation or injection or any skin penetration. In the present study, tDCS will be delivered for 1 hr each day for 3 days a week for 5 weeks in conjunction with constraint-induced movement therapy for the affected hand.
Study NCT01539096 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Constraint induced movement therapy (CIMT)
Description: Patients with stroke affecting the hand will receive constraint-induced movement therapy (CIMT) to re-train movements of the affected hand. Training will involve practicing tasks of daily living with qualified personnel. Training will be delivered for 1 hr each day for 3 days a week for 5 weeks. Patients will also be asked to use their affected hand in daily activities at home for 5 hrs a day while wearing a mitt on the unaffected hand.
Study NCT01539096 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Constraint induced movement therapy (CIMT)
Description: Patients with stroke affecting the hand will receive constraint-induced movement therapy (CIMT) to re-train movements of the affected hand. Training will involve practicing tasks of daily living with qualified personnel. Training will be delivered for 1 hr each day for 3 days a week for 5 weeks. Patients will also be asked to use their affected hand in daily activities at home for 5 hrs a day while wearing a mitt on the unaffected hand.
Study NCT01539096 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS: placebo noninvasive brain stimulation
Description: Placebo set-up for noninvasive brain stimulation will be similar to that for the active tDCS; sponge electrodes would be placed on the scalp and connected to a batter-operated device. Patients will not receive the effective level of direct current as would delivered in active tDCS intervention. But patients will not be able to decipher whether they are receiving active or placebo tDCS.
Study NCT02964039 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Error reduction
Description: During training sessions, a custom-built force-field will exert forces on the legs while participants walk. These forces will push the legs toward mechanically-appropriate mediolateral locations, having the effect of reducing the errors in foot placement that are often present among individuals who have experienced a stroke.
Study NCT02964039 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Error augmentation
Description: During training sessions, a custom-built force-field will exert forces on the legs while participants walk. These forces will push the legs away from mechanically-appropriate mediolateral locations, having the effect of amplifying the errors in foot placement that are often present among individuals who have experienced a stroke.
Study NCT02964039 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Activity matched control
Description: During training sessions, participants will interface with a custom-built force-field while they walk. The force-field will essentially get out of the way, producing minimal forces on the legs, and having no direct effect on the errors in foot placement that are often present among individuals who have experienced a stroke.
Study NCT00718081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral sufentanil
Description: Oral dosage of sufentanil
Study NCT01934816 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intradermal injections of GLP-1 and its analogues
Description: native GLP-1,Exenatide (Byetta)and Liraglutide (Victoza) will be microinjected at the same visit in no particular order in all study arms
Study NCT01934816 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intradermal injections of GLP-1 and its analogues
Description: native GLP-1,Exenatide (Byetta)and Liraglutide (Victoza) will be microinjected at the same visit in no particular order in all study arms
Study NCT01934816 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Intradermal injections of GLP-1 and its analogues
Description: native GLP-1,Exenatide (Byetta)and Liraglutide (Victoza) will be microinjected at the same visit in no particular order in all study arms
Study NCT01899352 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Tracheostomy
Description: Percutaneous and surgical tracheostomies will be performed with the procedure currently available in clinical practice.
Study NCT02577653 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Posturographic evaluation
Description: Subjects will undergo CDP testing using the modified Clinical Testing of Sensory Integration in Balance (mCTSIB) protocol. Subsequently, subjects will be asked to stand first on the right leg and then on the left leg with eyes open. Finally, subjects will be asked to perform 10 repetition of the squatting movement, with the operator pacing them (telling them when to start and when to stop the movements).
Study NCT03254147 — intervention group
Intervention type: DRUG
Intervention: dabigatran
Description: Non-vitamin K dependent oral anti-coagulants (NOACs)
Study NCT03254147 — intervention group
Intervention type: DRUG
Intervention: Apixaban
Description: Non-vitamin K dependent oral anti-coagulants (NOACs)
Study NCT03254147 — intervention group
Intervention type: DRUG
Intervention: Edoxaban
Description: Non-vitamin K dependent oral anti-coagulants (NOACs)
Study NCT03254147 — intervention group
Intervention type: DRUG
Intervention: Rivaroxaban
Description: Non-vitamin K dependent oral anti-coagulants (NOACs)
Study NCT02197104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: citocoline
Description: Ten subjects will receive 1,000mg once daily of citicoline. Each subject will stay on the study drug for 12 months. The outcome measures will be assessed at baseline and then again at the end of month 3, month 6, and month 12. The subjects will continue taking the same study drug at the same dose throughout the entire trial.
Study NCT02083263 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bilevel
Description: 3 months
Study NCT02083263 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PEP mask
Description: 3 months
Study NCT02330263 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: carbohydrate beverage
Description: 400ml of 12.8 g/100 ml carbohydrate beverage
Study NCT03380481 — intervention group
Intervention type: OTHER
Intervention: observational only-no intervention
Description: Observational only and no predesigned interventions in this study.
Study NCT00919490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-333
Description: Tablet, see arms for interventional description
Study NCT00919490 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet, see arms for interventional description.
Study NCT01803737 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Behavioral Weight Loss Intervention (SBWL)
Description: Included changing eating behaviors, increasing physical activity, and attending regular group weight loss meetings.
Study NCT01803737 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Campaign Intervention (CI)
Description: Included changing eating behaviors and increasing physical activity, however participants will not attend regular meetings. Instead they will attend two weekly meetings at weeks 0 and 12. During the weeks they are not scheduled to attend in-person weekly meetings (weeks 1-11), they will receive education materials via e-mail. They will also have the opportunity to earn points towards prizes by reporting diet and physical activity behaviors, and body weight via e-mail.
Study NCT03091491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab 1 mg/kg administered every 6 weeks as a 30 min IV infusion
Study NCT03091491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 3 mg/kg administered every 2 weeks as a 30 min IV infusion
Study NCT00718081 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral dosage of placebo
Study NCT04330326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metabolic Cofactor Supplementation
Description: Subjects in active treatment will receive dietary supplementation with N-acetylcysteine, L-carnitine tartrate, nicotinamide riboside, and serine, administered as a mixture. Half dosage of the co-factors will be given for two weeks (one dose taken just after dinner), and full dosage for 8 weeks (two equal doses taken just after breakfast and dinner).
Study NCT04330326 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sorbitol
Description: As placebo, sorbitol (5 g) flavored with strawberry aroma and coloring agent will be given. Sorbitol is widely used due to its solubility in water. It's approved by the U.S. Food and Drug Administration (FDA).
Study NCT02394145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Patients with normal kidney function and ESRD on hemodialysis will be treated by ticagrelor 90mg twice a day for 14 days. After then, platelet reactivity will be assessed by light aggregometry and VerifyNow assay.
Study NCT02394145 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: Patients with normal kidney function and ESRD on hemodialysis will be treated by ticagrelor 90mg twice a day for 14 days. After then, platelet reactivity will be assessed by light aggregometry and VerifyNow assay.
Study NCT02394145 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Patients with normal kidney function and ESRD on hemodialysis will be treated by clopidogrel 75mg or 150mg once a day for 14 days. After then, platelet reactivity will be assessed by light aggregometry and VerifyNow assay.
Study NCT00357032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: belinostat
Description: Given IV
Study NCT00357032 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00244842 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: voclosporin
Description: voclosporin 0.2, 0.3, or 0.4 mg/kg po BID
Study NCT03929055 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Physiological assesment
Description: 1. Arterial blood gas analysis.~2. esophageal pressure variation during inspiration and expiration~3. Arterial blood pressure, central venous pressure (CVP), heart rate.~4. diaphragmatic contraction detected by ultrasound
Study NCT00244842 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03830177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Natural Treatment
Description: The participant will be given the treatment, which contains all natural ingredients, and a kit of all necessary materials to take home with them, which will include a set of instructions. The kit will contain the instruction handout and their treatment. They will be instructed to apply the treatment to their scalp, wait seven minutes, and then rinse their scalp. They will perform this entire procedure once per day for 14 days.
Study NCT00947050 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: dynamic physical exercise
Description: dynamic supine bicycle exercise for 6 minutes
Study NCT01931176 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rDEN2Δ30-7169 vaccine
Description: Administered at a dose of 10\^3 plaque-forming units (PFU); delivered by subcutaneous injection in the deltoid region of the upper arm
Study NCT01931176 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Delivered by subcutaneous injection in the deltoid region of the upper arm
Study NCT01403272 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DermaTherapy® Linen and underpads.
Description: DermaTherapy® Linen is a 100% synthetic silk-like fabric technology designed to provide a cleaner, drier and smoother surface between the skin and support systems for a healthy micro-climate.~Subjects in the DermaTherapy® Linen Group are compared to subjects receiving usual care - bed linen made of cotton-blend fabrics.
Study NCT03042702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kevetrin
Description: Kevetrin dose to associated cohort
Study NCT03849027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methoxyflurane
Description: Inhaled methoxyflurane will be administered using the disposable field inhaler device (Penthrop®) according to the recommended dosing schedule.